Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
Ivan O RosasNorbert BräuMichael WatersRonaldo C GoBradley D HunterSanjay BhaganiDaniel SkiestMariam S AzizNichola CooperIvor S DouglasSinisa SavicTaryn YoungsteinLorenzo Del SorboAntonio Cubillo GracianDavid J De La ZerdaAndrew UstianowskiMin BaoSophie DimonacoEmily GrahamBalpreet MatharuHelen SpotswoodLarry TsaiAtul MalhotraPublished in: The New England journal of medicine (2021)
In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615.).
Keyphrases
- coronavirus disease
- sars cov
- rheumatoid arthritis
- healthcare
- juvenile idiopathic arthritis
- endothelial cells
- mental health
- early onset
- rheumatoid arthritis patients
- public health
- primary care
- cardiovascular events
- respiratory syndrome coronavirus
- induced pluripotent stem cells
- risk factors
- health information
- pluripotent stem cells
- randomized controlled trial
- respiratory failure
- cardiovascular disease
- drug induced
- community acquired pneumonia
- clinical trial
- systemic lupus erythematosus
- intensive care unit
- health promotion
- mechanical ventilation